Corvus Prices 7.9M-Share Offering at $22.15 to Raise $175M
Corvus priced 7.9 million common shares at $22.15 each in an upsized offering, generating approximately $175.0 million in gross proceeds. The company intends to allocate net proceeds toward working capital, Phase 3 T-cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials, and general corporate purposes.
1. Successful Completion of Upsized Offering
Corvus Pharmaceuticals completed an upsized underwritten public offering of 9,085,778 shares of its common stock, including the full exercise of a 1,185,101-share option granted to the underwriters. The offering generated approximately $201.2 million in gross proceeds before deducting underwriting discounts, commissions and estimated offering expenses. All shares were issued by Corvus, marking the company’s largest single equity raise to date and significantly strengthening its balance sheet.
2. Planned Allocation of Net Proceeds
Corvus expects to deploy the net proceeds primarily for working capital and general corporate purposes. Specific uses include advancing its Phase 3 trial in peripheral T-cell lymphoma, funding Phase 2 studies in atopic dermatitis, hidradenitis suppurativa and asthma, and supporting capital expenditures as well as sales, marketing and administrative activities. Management indicated that the additional capital will extend the company’s development runway into the fourth quarter of 2026, covering planned trial initiations in multiple indications.
3. Lead Managers and Regulatory Framework
Jefferies and Goldman Sachs & Co. LLC served as lead book-running managers, with Mizuho as bookrunner and Ladenburg Thalmann as co-manager. The shares were offered under an SEC-declared effective shelf registration statement filed on Form S-3 (File No. 333-281318) and a Rule 462(b) registration statement that became effective upon filing on January 21, 2026. Final prospectus supplements are available on the SEC’s website, ensuring full compliance with disclosure requirements.
4. Strategic Implications for Corvus’s Pipeline
This financing underpins Corvus’s strategy to pioneer ITK inhibition in immuno-oncology and immunodermatology. The lead candidate, soquelitinib, is in a registrational Phase 3 program for relapsed/refractory PTCL and early-stage trials in atopic dermatitis, with additional clinical assets targeting cancer and inflammatory diseases. By securing a strengthened cash position, Corvus positions itself to advance multiple clinical milestones over the next 18 months while preserving flexibility for potential collaborations or additional capital raises.